GlassScriptPhysician profile
Jonathan R Insel
NPI 1053350728
$7,477.34
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,283 · 2020: $1,179 · 2021: $2,374 · 2022: $1,126 · 2023: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $806.94 | 2019-2022 | |
| Amgen INC. | $786.95 | 2019-2023 | Evenity, Prolia |
| Abbott Laboratories | $544.65 | 2019-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Corcept Therapeutics | $460.20 | 2019-2022 | |
| Mannkind Corporation | $443.05 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $406.57 | 2019-2023 | |
| Lilly USA, LLC | $384.32 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.14 | 2019-2021 | |
| Abbvie INC. | $331.20 | 2019-2023 | |
| Radius Health, INC. | $272.20 | 2019-2022 | |
| Amarin Pharma, INC. | $270.68 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $255.05 | 2019-2021 | |
| Horizon Therapeutics Plc | $206.84 | 2019-2023 | Tepezza |
| Dexcom, INC. | $198.43 | 2021-2022 | |
| Insulet Corporation | $147.79 | 2019-2023 | Omnipod |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Insel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.